State lawmakers could add a card to the frequently shuffled deck of legislation the consumer health products industry will manage in 2024 by considering limiting access to OTC oral phenylephrine nasal decongestants due to doubts about the ingredient’s efficacy.
State Lawmakers Likely To Deal Questions About Oral Phenylephrine Into 2024 Legislation Deck
State government authority is limited to make changes concerning OTC sales, including oral products with phenylephrine. “As we've learned in the past, that hasn't stopped them before. We're going to be monitoring this very closely going into next year,” says CHPA state legislature lobby chief Carlos Gutierrez.
More from Legislation
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
The Washington State Department of Ecology publishes ‘Interim Policy on Lead in Cosmetics’ which provides safe harbor options for cosmetic products struggling with the 1ppm limit under the state’s Toxic Free Cosmetics Act, while the department gathers information under a newly opened rulemaking to ‘identify a feasible approach to regulating lead in cosmetic products.’
• By
The Washington Department of Ecology hasn’t backed down on its targeting of formaldehyde-releasing preservatives under the state’s Toxic-Free Cosmetics Act, as industry still awaits a draft final rule. In a recent webinar, attorney Angela Deisch of Amin Wasserman Gurnani, LLP said the department has also not provided clarity on penalties under the law, which goes into effect 1 January.
• By
The FDA's current leader, whose term will end with Donald Trump’s second inauguration, also described three qualities the agency’s next commissioner will need to succeed, including "believing that there is such a thing as expertise."
More from Policy & Regulation
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.